Paclitaxel

Generic Name
Paclitaxel
Brand Names
Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin
Drug Type
Small Molecule
Chemical Formula
C47H51NO14
CAS Number
33069-62-4
Unique Ingredient Identifier
P88XT4IS4D
Background

Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication

Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions
Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer
Associated Therapies
-
Clinical Trials
Related News

TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer

First Posted Date
2022-01-12
Last Posted Date
2022-06-24
Lead Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Target Recruit Count
376
Registration Number
NCT05188313
Locations
🇳🇱

Academic Medical Center, Amsterdam, Netherlands

Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC

First Posted Date
2022-01-12
Last Posted Date
2022-02-25
Lead Sponsor
Sichuan Cancer Hospital and Research Institute
Target Recruit Count
80
Registration Number
NCT05189730
Locations
🇨🇳

Sichuan Cancer Hospital and Research Institute, Chengdu, Sichuan, China

Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer

First Posted Date
2022-01-12
Last Posted Date
2022-01-12
Lead Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Target Recruit Count
190
Registration Number
NCT05189067
Locations
🇨🇳

2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer

First Posted Date
2022-01-11
Last Posted Date
2024-12-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
70
Registration Number
NCT05185947
Locations
🇺🇸

National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer

Phase 4
Recruiting
Conditions
Breast Cancer
Interventions
Drug: Paclitaxel
First Posted Date
2022-01-10
Last Posted Date
2024-12-19
Lead Sponsor
University of Michigan Rogel Cancer Center
Target Recruit Count
22
Registration Number
NCT05183126
Locations
🇺🇸

University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States

Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer

First Posted Date
2022-01-05
Last Posted Date
2024-10-24
Lead Sponsor
M.D. Anderson Cancer Center
Registration Number
NCT05177796
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

First Posted Date
2021-12-30
Last Posted Date
2024-11-21
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
280
Registration Number
NCT05173987
Locations
🇺🇸

Northside Hospital ( Site 0017), Atlanta, Georgia, United States

🇺🇸

St. Dominic's Hospital ( Site 0024), Jackson, Mississippi, United States

🇺🇸

John Theurer Cancer Center at Hackensack University Medical Center ( Site 0026), Hackensack, New Jersey, United States

and more 192 locations

Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

First Posted Date
2021-12-15
Last Posted Date
2022-04-26
Lead Sponsor
Kosei Hasegawa, MD, PhD
Target Recruit Count
35
Registration Number
NCT05158062
Locations
🇯🇵

Saitama Medical Uiversity International Medical Center, Hidaka, Saitama, Japan

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients with Advanced Non-small Cell Lung Cancer

First Posted Date
2021-12-02
Last Posted Date
2024-11-21
Lead Sponsor
BioNTech SE
Target Recruit Count
160
Registration Number
NCT05142189
Locations
🇺🇸

Norton Cancer Institute, Louisville, Kentucky, United States

🇺🇸

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

🇺🇸

NEXT Virginia, Fairfax, Virginia, United States

and more 35 locations

Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

First Posted Date
2021-11-29
Last Posted Date
2023-12-20
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
28
Registration Number
NCT05136846
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

🇺🇸

City of Hope, Duarte, California, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy